Results 111 to 120 of about 243,931 (299)
Transparency of regulation and cross-border bank mergers [PDF]
, 2008 Although there is anecdotal evidence that merger control may constitute a barrier to the integration of European retail banking markets, systematic empirical evidence is missing until now. This paper aims to fill this gap.
Köhler, Matthias
core +2 more sources
Black hole masses and starbursts in X-shaped radio sources
, 2011 It has been suggested that the X-shaped morphology observed in some radio sources can reflect either a recent merger of two supermassive black holes (SMBHs) or the presence of a second active black hole in the galactic nucleus. These scenarios are tested
A. P. Lobanov +56 more
core +1 more source
Molecular Oncology, EarlyView.A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
The Allocation of Jurisdiction in International Antitrust [PDF]
In this paper, we consider the organisation of international antitrust as an issue of institution design which involves a trade-off between an inadequate internalisation of external effects across jurisdictions and the risk of capture in a centralised ...
Damien J. NEVEN, Lars-Hendrik RÖLLER
core
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Molecular Oncology, EarlyView.Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son +13 more
wiley +1 more source
Molecular Oncology, EarlyView.We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto +8 more
wiley +1 more source
New Observational Recipes for Measuring Dynamical States of Galaxy Clusters
The Astrophysical JournalDuring cluster assembly, a cluster’s virialization process leaves behind signatures that can provide information on its dynamical state. However, no clear consensus yet exists on the best way to achieve this.
Hyowon Kim +6 more
doaj +1 more source
A Treatment Effect Method for Merger Analysis with an Application to Parking Prices in Paris [PDF]
Most retrospective merger studies resort to the treatment effect approach, comparing the price dynamics in a treatment group and in a control group.
Laurent Linnemer, Philippe Choné
core